Coinbase CEO’s Longevity Startup NewLimit Raises $435 Million

TLDR

• NewLimit, co-founded by Coinbase CEO Brian Armstrong, raised $435 million, pushing its valuation to $3.1 billion
• The valuation is more than triple what it was less than a year ago, when it was below $1 billion
• The company focuses on reversing cellular aging through epigenetic reprogramming, with no products on market yet
• NewLimit plans to start its first human clinical trials in 2027, targeting alcohol-related liver disease
• The startup has no crypto or blockchain connection — it is a traditional biotech venture capital investment

---

Brian Armstrong built his name and fortune in crypto. Now he is betting hundreds of millions of dollars on something entirely different: making human cells young again.

Coinbase Co-Founder Brian Armstrong;s Longevity Startup NewLimit Raises $435M Series C

NewLimit, a longevity biotech startup co-founded by Coinbase CEO Brian Armstrong, announced a $435 million Series C round led by Founders Fund. New investors including Thrive Capital,… pic.twitter.com/nMPiPF8lHZ

— Wu Blockchain (@WuBlockchain) June 3, 2026

NewLimit, the San Francisco biotech company Armstrong co-founded, just closed a $435 million funding round. The deal puts the company’s post-money valuation at $3.1 billion — more than triple the valuation it carried during its Series B round less than a year ago.

Armstrong started NewLimit in 2022 alongside Blake Byers and Jacob Kimmel. Kimmel previously worked at Calico, the longevity research lab owned by Alphabet.

The company is built on a concept called epigenetic reprogramming. As people age, their cells do not lose their DNA — but they do lose the ability to read it the same way they did in youth. NewLimit is developing drugs that use molecular tools called transcription factors to reset gene expression in aged cells back to younger patterns.

The delivery method uses lipid nanoparticles, the same core technology behind mRNA COVID vaccines.

Where the Science Stands

NewLimit has not tested its drugs in humans yet. The company has conducted preclinical work, including human cell screens and animal studies, but human trials are still ahead.

The plan is to file for its first clinical trial in 2027, targeting alcohol-related liver disease. The liver, immune system, and vasculature are the company’s initial areas of focus.

The $3.1 billion valuation is based entirely on that preclinical work.

NewLimit is pursuing what researchers call partial epigenetic reprogramming. The goal is a limited reset of cellular age — not a full return to a stem-cell-like state, which could carry cancer risks.

The funding history shows how fast investor confidence has grown. NewLimit raised a $130 million Series B in May 2025, led by Kleiner Perkins. The new round, which closed last Friday, is more than three times that amount raised in a single close.

What This Has to Do With Crypto

The short answer is: nothing. NewLimit has no token, no blockchain component, and no on-chain product. Armstrong’s role at Coinbase is separate from his work at NewLimit.

For investors who follow Armstrong because of his role building one of the world’s largest crypto exchanges, this is a purely traditional biotech venture capital investment.

The ability to raise $435 million before a single human trial suggests strong institutional backing. Kleiner Perkins led the prior round and remains involved.

NewLimit now joins a growing list of longevity startups backed by technology billionaires. The next major milestone will come when the company submits its clinical trial application, expected in 2027.